376 related articles for article (PubMed ID: 26362253)
1. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease.
Suzuki M; Fujikake N; Takeuchi T; Kohyama-Koganeya A; Nakajima K; Hirabayashi Y; Wada K; Nagai Y
Hum Mol Genet; 2015 Dec; 24(23):6675-86. PubMed ID: 26362253
[TBL] [Abstract][Full Text] [Related]
2. Pathological role of lipid interaction with α-synuclein in Parkinson's disease.
Suzuki M; Sango K; Wada K; Nagai Y
Neurochem Int; 2018 Oct; 119():97-106. PubMed ID: 29305919
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase reduces the spread of protein aggregation in a Drosophila melanogaster model of neurodegeneration by regulating proteins trafficked by extracellular vesicles.
Jewett KA; Thomas RE; Phan CQ; Lin B; Milstein G; Yu S; Bettcher LF; Neto FC; Djukovic D; Raftery D; Pallanck LJ; Davis MY
PLoS Genet; 2021 Feb; 17(2):e1008859. PubMed ID: 33539341
[TBL] [Abstract][Full Text] [Related]
4. Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.
Davis MY; Trinh K; Thomas RE; Yu S; Germanos AA; Whitley BN; Sardi SP; Montine TJ; Pallanck LJ
PLoS Genet; 2016 Mar; 12(3):e1005944. PubMed ID: 27019408
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
[TBL] [Abstract][Full Text] [Related]
6. Lipids as
Ikenaka K; Suzuki M; Mochizuki H; Nagai Y
Front Neurosci; 2019; 13():693. PubMed ID: 31333408
[TBL] [Abstract][Full Text] [Related]
7. TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease.
Seo BA; Kim D; Hwang H; Kim MS; Ma SX; Kwon SH; Kweon SH; Wang H; Yoo JM; Choi S; Kwon SH; Kang SU; Kam TI; Kim K; Karuppagounder SS; Kang BG; Lee S; Park H; Kim S; Yan W; Li YS; Kuo SH; Redding-Ochoa J; Pletnikova O; Troncoso JC; Lee G; Mao X; Dawson VL; Dawson TM; Ko HS
Neuron; 2021 Dec; 109(23):3758-3774.e11. PubMed ID: 34644545
[TBL] [Abstract][Full Text] [Related]
8. The effect of mutant GBA1 on accumulation and aggregation of α-synuclein.
Maor G; Rapaport D; Horowitz M
Hum Mol Genet; 2019 Jun; 28(11):1768-1781. PubMed ID: 30615125
[TBL] [Abstract][Full Text] [Related]
9. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
Stojkovska I; Krainc D; Mazzulli JR
Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
[TBL] [Abstract][Full Text] [Related]
11. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
12. Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models.
Burbulla LF; Zheng J; Song P; Jiang W; Johnson ME; Brundin P; Krainc D
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622801
[TBL] [Abstract][Full Text] [Related]
13. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
[TBL] [Abstract][Full Text] [Related]
14. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
15. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
Kim MJ; Jeon S; Burbulla LF; Krainc D
Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
[TBL] [Abstract][Full Text] [Related]
17. VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease.
Miura E; Hasegawa T; Konno M; Suzuki M; Sugeno N; Fujikake N; Geisler S; Tabuchi M; Oshima R; Kikuchi A; Baba T; Wada K; Nagai Y; Takeda A; Aoki M
Neurobiol Dis; 2014 Nov; 71():1-13. PubMed ID: 25107340
[TBL] [Abstract][Full Text] [Related]
18. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.
Sardi SP; Clarke J; Viel C; Chan M; Tamsett TJ; Treleaven CM; Bu J; Sweet L; Passini MA; Dodge JC; Yu WH; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3537-42. PubMed ID: 23297226
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
20. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation.
Bae EJ; Yang NY; Lee C; Lee HJ; Kim S; Sardi SP; Lee SJ
Exp Mol Med; 2015 Mar; 47(3):e153. PubMed ID: 25813221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
